Monitor for any commentary on real-world usage or physician adoption during the peer exchange session, which could signal uptake trends. No material change to near-term revenue expectations.
Price Chart
Executive Summary
Ardelyx announced that data on the long-term effects of XPHOZAH (tenapanor) on serum electrolytes and nutrition biomarkers will be presented at the National Kidney Foundation’s Spring Clinical Meetings in May 2026. The presentation reinforces the safety and mechanism of action of XPHOZAH, a phosphate absorption inhibitor for dialysis patients with hyperphosphatemia.
Key Facts
- Ardelyx will present long-term data on XPHOZAH at the NKF Spring Clinical Meetings (May 7–10, 2026).
- The poster presentation focuses on XPHOZAH's impact on serum electrolytes and nutrition biomarkers without altering key electrolytes.
- XPHOZAH is approved to reduce serum phosphorus in CKD patients on dialysis who don't respond to or tolerate phosphate binders.
- Diarrhea remains the most common side effect, occurring in 43–53% of patients, with 5% experiencing severe cases.
- Ardelyx is also sponsoring a peer exchange session to discuss XPHOZAH’s use in clinical practice.
Financial Impact
No immediate financial impact — this is clinical data dissemination, not a commercial or regulatory milestone.
Risk Factors
- Limited commercial uptake of XPHOZAH despite clinical data.
- High insider selling activity ($262K in past 30 days) may indicate lack of confidence despite positive sentiment from analysts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281589 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 22d ago | Press Release | $3.39 | awaiting T+20 | — | $2.99 (−11.73%) |
Aug 25, 2026 8w ago | Insider Cluster | $3.83 $3.45 | ▼ −9.92% | ▼ −10.15% | $2.99 (−21.87%) |
Aug 25, 2026 8w ago | Insider Cluster | $3.83 $3.45 | ▼ −9.92% | ▼ −10.15% | $2.99 (−21.87%) |
Aug 21, 2026 9w ago | 144 | $3.74 $3.62 | ▼ −3.21% | ▼ −4.52% | $2.99 (−19.99%) |
Aug 21, 2026 9w ago | 144 | $3.74 $3.62 | ▼ −3.21% | ▼ −4.52% | $2.99 (−19.99%) |
Aug 17, 2026 10w ago | 8-K | $3.92 $3.40 | ▼ −13.27% | ▼ −12.28% | $2.99 (−23.66%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.06 $3.52 | ▼ −13.30% | ▼ −11.77% | $2.99 (−26.30%) |
Jul 2, 2026 16w ago | 8-K | $5.27 $5.04 | ▼ −4.36% | ▼ −3.95% | $2.99 (−43.22%) |
Jun 17, 2026 18w ago | 8-K | $6.05 $5.13 | ▼ −15.29% | ▼ −15.82% | $2.99 (−50.54%) |
Jun 15, 2026 19w ago | 144 | $5.67 $5.16 | ▼ −8.99% | ▼ −9.19% | $2.99 (−47.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers